Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - HC Wainwright reduced their Q2 2025 EPS estimates for OPKO Health in a research report issued to clients and investors on Thursday, May 1st. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($0.10) per share for the quarter, down from their previous estimate of ($0.07). HC Wainwright has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health's Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.34) EPS.

Several other analysts also recently issued reports on OPK. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating on the stock. StockNews.com downgraded OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday. Finally, Barrington Research restated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, OPKO Health currently has an average rating of "Hold" and an average target price of $2.75.

OPKO Health Price Performance

Shares of OPKO Health stock traded down $0.04 on Monday, hitting $1.25. The company's stock had a trading volume of 4,221,443 shares, compared to its average volume of 3,894,115. The company has a market capitalization of $987.35 million, a P/E ratio of -6.55 and a beta of 1.42. OPKO Health has a 52-week low of $1.15 and a 52-week high of $2.04. The firm has a fifty day moving average price of $1.60 and a 200-day moving average price of $1.57. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business's revenue for the quarter was down 13.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.12) earnings per share.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 67,434 shares of the company's stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average price of $1.71 per share, with a total value of $115,312.14. Following the transaction, the chief executive officer now owns 213,301,448 shares in the company, valued at $364,745,476.08. This trade represents a 0.03 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased 767,434 shares of company stock valued at $1,238,312 in the last ninety days. Company insiders own 49.69% of the company's stock.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently made changes to their positions in the business. Barclays PLC increased its holdings in OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock valued at $810,000 after purchasing an additional 329,870 shares in the last quarter. Virtu Financial LLC acquired a new position in OPKO Health during the 3rd quarter worth approximately $120,000. World Investment Advisors LLC purchased a new position in OPKO Health in the 3rd quarter worth approximately $61,000. PFG Investments LLC boosted its holdings in OPKO Health by 9.4% in the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company's stock worth $1,707,000 after acquiring an additional 99,795 shares during the period. Finally, Capital Advisors Inc. OK acquired a new stake in OPKO Health in the fourth quarter valued at approximately $220,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.